| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2025 | Chromologics raises €7 million to bring its natural colour ingredients closer to market | Chromologics raises €7 million to bring its natural colour ingredients closer to market
Tue, Nov 18, 2025 09:00 CET Report this content
Copenhagen, Denmark. November 13, 2025, – Chromologics, a Danish biotech company developing fermentation... |
| Nov 16, 2025 | Novo Chairman Blames Board Dropout on Former Employer Pfizer | |
| Oct 31, 2025 | Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by "Championing the Missions that Matter™" | TAMPA, Fla., Oct. 31, 2025 /PRNewswire/ -- Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment... |
| Oct 10, 2024 | US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal | Boards, Policy & RegulationGovernment
Regulatory Oversight
Mergers & Acquisitions
Health
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
By Jody GodoyOctober 10, 20241:18 PM UTCUpdated ago
Text
Small Text
Medium... |
| Sep 28, 2024 | [Weekly funding roundup Sept 21-27] VC inflow continues to show strong traction
Recommended Stories For You | Venture capital funding into Indian startups continues to remain high given the inflow of large-value deals in September.
The last week of the month saw total funding reach $430 million spread across 24 deals. In contrast, the previous week... |
| Jul 7, 2021 | Novo Holdings A/S Invests in US Healthcare IT Company Availity | JACKSONVILLE, Fla., July 7, 2021 /PRNewswire/ -- Novo Holdings A/S ("Novo Holdings" and "NH"), a leading international investor in healthcare and life sciences, today announced a strategic minority investment in Availity... |
| Jun 2, 2017 | Inthera Bioscience Raises CHF 10.5 Million in Series A Financing Round | |
| Mar 28, 2017 | Avista and Nordic Capital announce the proposed sale of a 19.95% shareholding in ConvaTec Group Plc to Novo A/S (the investment holding company of the Novo Nordisk Foundation) and a proposed placing of approximately 300 million ordinary shares | March 28, 2017 – Nordic Capital and Avista (each as defined below) have today agreed the sale of a 19.95% shareholding (the “Sale”) in ConvaTec Group Plc (“ConvaTec”) to Novo A/S, the investment holding company in the Novo group, responsibl... |
| Jan 17, 2017 | Amra Raises $9m in Funding | Amra, a Linkoping, Sweden-based digital health company, raised $9m in funding.
The round was co-led by Pfizer Venture Investments and Novo Seeds with participation from Industrifonden.
The company intends to use the funds to establish itsel... |
| Jun 22, 2016 | After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle | Novo A/S has named Kasim Kutay as its CEO four months after parting company with former leader Eivind Kolding. The appointment puts Kutay, a healthcare banking veteran, in charge of an investment vehicle that lists a 27% stake in Novo Nordi... |
| Jan 27, 2016 | Daily funding roundup - January 27, 2016 | Tarveda Therapeutics secured $38M; Branch Metrics received $35M investment; PitchBook raised $10M
CosmosID, a bioinformatics company focused on microorganisms and infectious diseases, today announced it has closed $6 million in Series B fun... |
| Dec 28, 2015 | How to get funding for you startup in Denmark | Nicolaj Højer Nielsen has an impressive track record as both a serial entrepreneur and an investor in Denmark. He has co-founded, among other businesses, CodeSealer and Sepior, and invested in many Danish startups, such as Penneo. Read his ... |
| Dec 14, 2015 | Inthera Bioscience raises EUR 3.4 million in seed financing round | |
| Nov 24, 2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| Nov 23, 2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| Jul 24, 2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M
AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| Jul 22, 2015 | Daily funding roundup - July 22, 2015 | Events.com has now raised a total of $17M; Darktrace landed $22.5M; Kinetic Social closed $17.5M
Events.com has raised a new round of funding. The size of the round was undisclosed, but it was led by Arctaris and with participation from La ... |
| May 21, 2015 | Biosyntia Completes US$1.9M Funding | Biosyntia ApS, a Denmark-based biotech company that develops processes for biological production of vitamins, completed a Danish KR12.5m (approx. US$1.9m) funding round.
The round was led by Novo Seeds. In conjunction with the funding, Søre... |
| Sep 30, 2014 | Allakos Raises $10M in Funding | Allakos, a San Francisco Bay Area-based biotechnology company, raised an additional $10m in funding.
Backers included current investors Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
The company, which ... |
| Sep 29, 2014 | Pulmologix Raises €9.6M | Pulmologix, a Stockholm, Sweden-based developer of a new oral non-steroidal anti-asthmatic drug, raised €9.6M in Series B funding.
The round was led by Novo Seeds and Sunstone Capital with participation from previous investors Forbion Capit... |
| May 24, 2014 | Biotech company wants to be first with OTC sleep aid that’s also a snoring remedy | Requis is preparing to submit an investigational new drug application for Requisom to the U.S. Food and Drug Administration.
There is currently no drug available to prevent snoring so a sleep aid that can do that has the potential to get a ... |
| May 23, 2014 | Lysogene Raises €16.5M in Series A Funding | Lysogene, a Paris, Germany-based gene therapy company, raised €16.5m in Series A funding.
The round was led by Sofinnova Partners, with participation from Bpifrance‘s Innobio fund and Novo Seeds, which is part of Novo A/S. In conjunction wi... |
| May 23, 2014 | The Xconomy SF Six: Big Name Investors, Funding for Clarizen, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Here are the top six things we’re paying attention to in the San Francisco tech scene this week.
—iRhythm Technologies, maker of technology to improve the diagnosis of heart a... |
| May 22, 2014 | Cardiac patch to detect arrhythmias draws $17 million in Series E round | The U.S. Food and Drug Administration gave 510(k) clearance to iRhythm’s Zio Patch in 2009, and it was introduced commercially in 2011.
Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently dur... |
| May 9, 2014 | Anokion Closes $37.5M Series A Financing Round | Anokion SA, a Lausanne, Swuitzerland-based developer of a technology for retraining white blood cells to induce therapeutic immune tolerance, closed a CHF33m (approximately $37.5m) Series A financing round.
The round was co-led by Novartis ... |
| May 5, 2014 | Swiss biotech start-up Anokion closes financing round for CHF 33 Million | |
| Apr 17, 2014 | Nora Therapeutics Closes $18M Series B Financing | Nora Therapeutics, a Palo Alto, CA-based biotechnology company focused on developing reproductive therapeutics, closed an $18m Series B financing.
The round was led by Novo A/S with participation from existing investors Burrill & Compan... |
| Apr 15, 2014 | PanOptica Closes Up To $45M in Series B Funding | PanOptica, a Bernardsville, NJ-based biopharmaceutical company focused on ophthalmology therapies, closed up to $45m in Series B funding.
The round was led by Novo Ventures and Third Rock Ventures with participation from SV Life Sciences.
T... |
| Feb 24, 2014 | Thesan Pharmaceuticals Closes $49M Series B Financing | Thesan Pharmaceuticals, a Carlsbad CA-based developer of novel approaches for the treatment of dermatological disorders, closed a $49m Series B financing.
The round was led by current investor Novo Ventures with participation from SV Life S... |
| Nov 6, 2013 | Delenex Therapeutics closes CHF 7.3 Million Series A3 Financing | |
| Aug 29, 2013 | ObsEva SA announces CHF 32 Million funding | |
| Aug 29, 2013 | ObsEva Closes CHF32M Series A Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine, closed a CHF32m (approximately €25.6m) Series A financing round.
The round was led by Sofinnov... |
| May 21, 2013 | 3i makes a 2.3x return on the sale of Xellia | 3i Group plc (“3i”), and funds managed by 3i, announce they have agreed to sell Xellia Pharmaceuticals A/S (“Xellia”), a specialty pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infectiv... |
| May 3, 2013 | Symphogen Closes Additional €41M Financing | Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibody mixtures, closed an additional €41m financing.
Backers included Novo A/S and PKA with investments of €20 million each, and Danica Pension... |
| Dec 17, 2012 | Allakos Completes $32M Series A Financing | Allakos Inc., a San Francisco Bay Area-based biotechnology company, has completed a $32m Series A financing.
The round was led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
In... |
| Dec 4, 2012 | Flexion Therapeutics Raises $20M in Series B Financing | Flexion Therapeutics, a Woburn, MA-based company that discovers and develops innovative therapeutics for musculoskeletal disorders, has raised $20m in Series B financing.
The round led by new investor Novo Ventures, with participation from ... |
| Oct 31, 2012 | Thesan Pharmaceuticals Closes $16M Series A Financing | Thesan Pharmaceuticals, a San Clemente CA-based biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions, has closed a $16m Series A financing.
The round was co-led... |
| Jul 23, 2012 | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | With cystic fibrosis the goal is to improve lung function and reduce pulmonary exacerbation. In a Phase 3 clinical study, Ataluren demonstrated trends in improvement in lung function when compared to a placebo. There were also trends in imp... |
| Apr 4, 2012 | Denator Raises SEK25.5M in Sixth Financing | Denator AB, a Gothenburg, Sweden-based develops, markets and sells instruments and consumables to address needs in the life science and clinical research markets, has raised SEK25.5m in its sixth financing.
Backers include Novo Seeds and Al... |
| Mar 16, 2012 | Tarsa Therapeutics Closes $28M Series B Equity Financing | Tarsa Therapeutics, Inc., a Philadelphia, PA-based developer of a novel oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis, has closed a $28m Series B equity financing.
The round was led by new in... |
| Mar 16, 2012 | Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | The drug is a peptide hormone that would be destroyed by the digestive system if taken orally, but the technology behind the drug is intended to prevent that from happening.
The technology is licensed from Unigene. Under the terms of the ag... |
| Jan 4, 2012 | Novo Leads New $30M Round for San Diego’s Elevation Pharmaceuticals | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
San Diego’s Elevation Pharmaceuticals says today it’s raised $30 million in Series B funding, which is expected to carry the startup through its mid-stage trials for a new aer... |
| Sep 9, 2011 | Orphazyme Completes €14M Series A Financing | Orphazyme ApS, a Copenhagen, Denmark-based biopharmaceutical company that develops innovative medicines for the treatment of a family of genetic disorders called lysosomal storage diseases, completed a €14m Series A financing round.
Partici... |
| Jun 12, 2009 | Anti-viral developer Alios raises $8M more for $32M | Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the ... |
| Apr 10, 2009 | Cell Biosciences to launch new tech with $10M | Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that... |
| Jul 9, 2007 | Reata Pharma draws $25M for cancer and inflammation drugs | Irving, Texas-based Reata Pharmaceuticals, a biotech working on new drugs to treat cancer and inflammation, raised $25 million in a fifth funding round. The round was led by existing investors, including CPMG and Novo A/S.
VentureBeat Ventu... |
| Jun 14, 2007 | Logical Therapeutics raises $30M, relocates to Boston area | Pittsburgh-based Logical Therapeutics, a developer of drugs for inflammation and metabolic disease, raised $30 million in a second funding round and announced it is moving its headquarters to a location “near Boston.” (What are the odds tha... |
| Aug 23, 2006 | US firm De Novo Ventures closes $300m life science fund | Fred Dotzler, a founder and managing director of De Novo Ventures, said, ‘De Novo Ventures III builds upon the suc |
| Cardiac patch to detect arrhythmias draws $17 million in Series E round | Cardiac rhythm diagnostics device maker iRhythm Technologies has raised $17 million, according to a company statement, as providers try to keep patients out of the hospital, but keep an eye on warning signs of worsening conditions. That tre... |
| RSPR Pharma initiates Phase II clinical trial of oral mast cell inhibitor CRD007 in uncontrolled asthma | Stockholm 2015-12-08
RSPR Pharma AB today announced the initiation of a phase II clinical proof of concept trial of CRD007 in asthma patients not fully controlled by inhaled corticosteroids and long acting beta-agonists (ICS/LABA). The stu... |
| Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | A biopharmaceutical company with a cystic fibrosis drug in late-stage development has raised $30 million, according to a company statement. It was about $10 million less than the original funding target listed in a form D document with the ... |
| Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | A therapeutics company has raised $28 million in a series B financing round in the run-up to submitting its new drug application later this year for its oral calcitonin remedy to treat and cure osteoporosis in postmenopausal women.
Tarsa Th... |
| RSPR Pharma hires Paul de Potocki as Chief Business Officer | Stockholm 2016-08-23
RSPR Pharma AB today announced that Paul de Potocki will join the company as CBO from September 19. Paul will be responsible for business development and commercial planning, including pricing, reimbursement and market... |
| Biotech company wants to be first with OTC sleep aid that’s also a snoring remedy | A biotech company developing an over-the-counter sleep aid came across an intriguing discovery — it also helps snoring. Requis Pharmaceuticals hopes to be the first company to develop a drug to prevent snoring that also functions as a sleep... |
| Pulmologix raises € 9.6 million to develop a new oral non-steroidal anti-asthmatic drug | Press release Stockholm 2014-09-16
Pulmologix AB today announced the closing of a series B financing of € 9.6 million to develop a new Oral Non-Steroidal Anti-asthmatic (ONSA) for the treatment of early onset allergic asthma.
Asthma is an... |